Supraventricular tachycardias include rapid arrhythmias whose mechanism originates in atrial tissue or the atrioventricular junction, or requires structures located at the level of the bundle of His or above it. The definition describes the system that generates or sustains the arrhythmia, not merely the morphology of the ventricular complex. A supraventricular tachycardia may present with a wide QRS because of bundle branch block, aberrant conduction or activation through an accessory pathway; conversely, the apparent regularity of a rapid rhythm does not automatically identify its origin.
In practice, the term is often used more narrowly for paroxysmal episodes caused by nodal or atrioventricular re-entry. This convention is useful only if it does not erase the differences among mechanisms. Atrial arrhythmias belong anatomically to the supraventricular group, but atrial fibrillation, flutter and atrial tachycardias require their own pathways of care, particularly for substrate, ablation and thromboembolic prevention. Paroxysmal supraventricular tachycardia, by contrast, is a clinical presentation that should be documented and attributed to the responsible circuit.
The distribution of the various forms changes with age and the population studied. Accessory pathways may present in childhood; nodal re-entry is frequently recognized in adolescents and adults, even in the absence of structural heart disease. Automatic junctional tachycardias are particularly relevant in pediatric patients and after cardiac surgery, whereas scars and atrial disease favor other forms with advancing age. Case series from ablation centers select symptomatic or complex patients and do not directly represent the frequency of arrhythmias in the general population.
The normal conduction system separates atrial from ventricular activation through the fibrous skeleton of the heart, leaving the atrioventricular node and His-Purkinje system to transmit the impulse. The atrioventricular node introduces a physiological delay that promotes filling and limits transmission of closely spaced atrial impulses. Its conduction depends to a substantial extent on calcium currents and responds to autonomic tone, vagal maneuvers and AV nodal drugs. This property explains why tachycardias generated at different sites may terminate with the same intervention.
In re-entry, a depolarization wavefront travels through a circuit and returns to tissue that has recovered excitability. Compatible relationships are required among pathway length, conduction velocity and refractoriness; a unidirectional block often allows initiation of the circuit. The two components do not have to be two separate macroscopic bundles. In AV nodal re-entry, heterogeneity of conduction properties and perinodal connections allows functionally distinct pathways. In atrioventricular re-entry, by contrast, an accessory connection creates a second link between atria and ventricles.
The concept of AV nodal dependence is more useful than the anatomical name alone. If the atrioventricular node is an indispensable passage in the circuit, transient block at that point can terminate the tachycardia. If the generator is located in atrial myocardium and continues to discharge autonomously, AV nodal block reduces the ventricular response and makes atrial activity more visible without necessarily eliminating it. This distinction prevents slowing of the pulse from being confused with resolution of the arrhythmia.
Enhanced automaticity results from acceleration of spontaneous depolarization in cells capable of repeatedly reaching threshold. An automatic focus may overdrive the sinus node when its rate increases or when the dominant rhythm slows. Onset and termination may be gradual, with progressive acceleration and deceleration; however, these features are not always recognizable in brief recordings. Catecholamines, fever, ischemia, metabolic abnormalities and postoperative injury can modify the activity of atrial and junctional tissue.
Triggered activity, by contrast, requires a preceding action potential. Oscillations of the membrane potential may reach threshold and generate a new impulse; intracellular calcium overload and adrenergic activation are relevant in some forms. The surface appearance may resemble that of an automatic focus or a small re-entry circuit. P-wave morphology approximately localizes the activation sequence but does not by itself identify the cellular mechanism.
The tissue forming the circuit and the tissue producing the visible ECG are not necessarily identical. In typical AV nodal re-entry, the atria and ventricles may be activated nearly simultaneously even though neither is necessarily an indispensable component of the circuit. In atrioventricular re-entry, by contrast, the usual pathway includes the atrioventricular node, conduction system, ventricle, accessory pathway and atrium. This difference becomes decisive during electrophysiological study, when appropriately timed stimuli determine which structures are required to maintain the arrhythmia.
The autonomic nervous system modifies conduction, refractoriness and the trigger threshold without constituting, in most cases, the anatomical cause of tachycardia. An episode after stress, physical activity or a sleepless night therefore does not demonstrate an exclusively emotional origin. Autonomic stimulation may activate a stable substrate that is present even during asymptomatic periods. The absence of an identifiable precipitating factor does not weaken a diagnosis supported by the tracing.
The most informative classification combines location, mechanism and participation of structures in the circuit. A subdivision based only on rate or QRS width is useful for initial orientation but does not represent a definitive taxonomy. Two patients with regular narrow-complex tachycardia may have AV nodal re-entry, atrioventricular re-entry or atrial tachycardia; differences may emerge from the relationship between P waves and QRS complexes, onset of the episode or maneuvers performed during electrophysiological study.
Atrioventricular nodal reentrant tachycardia, or AVNRT, uses different conduction and refractoriness properties within the nodal and perinodal system. In the typical form, anterograde conduction occurs over the slow pathway and retrograde conduction over the fast pathway. Retrograde atrial activation may be hidden within the QRS or deform its terminal portion. Atypical forms have different timing relationships and may produce a long RP interval; clearly visible P waves therefore do not exclude AV nodal re-entry.
Atrioventricular reentrant tachycardia, or AVRT, requires an accessory pathway. In the orthodromic form, the impulse reaches the ventricles through the atrioventricular node and His-Purkinje system and returns to the atria along the abnormal connection. The QRS is usually narrow, except in the presence of aberrancy or bundle branch block. In the antidromic form, the anterograde pathway uses the accessory connection and ventricular activation is pre-excited, producing a wide-complex tachycardia that requires a careful differential diagnosis.
A manifest pathway conducts anterogradely and may cause pre-excitation during sinus rhythm; a concealed pathway conducts only retrogradely and can sustain AVRT without a baseline delta wave. The distinction prevents two errors: excluding an accessory pathway because the sinus ECG is normal, or considering every pre-excitation pattern proof that a documented tachycardia uses that pathway. An accessory connection may be a concomitant finding and not participate in the observed arrhythmia.
Wolff-Parkinson-White syndrome combines pre-excitation with clinical tachyarrhythmias. The isolated electrocardiographic pattern and the syndrome are not equivalent terms. The specific risk derives mainly from the possibility that atrial fibrillation may be transmitted rapidly to the ventricles through a pathway with short anterograde refractoriness. That risk is not adequately described by the number of orthodromic episodes or how well they are tolerated: few symptoms may coexist with pathway properties that require dedicated assessment.
Permanent junctional reciprocating tachycardia, or PJRT, is a form of atrioventricular re-entry with slow, decremental retrograde conduction through an accessory pathway, often posteroseptal. The historical name does not indicate junctional automaticity and does not imply that the arrhythmia is always uninterrupted. The tendency to persistence, long-RP relationship and possible development of ventricular dysfunction distinguish it clinically from the brief episodes of many other AVRTs.
Mahaim accessory pathway tachycardias involve connections with distinctive properties, often right atriofascicular pathways with decremental anterograde conduction. The tachycardia may have a morphology resembling left bundle branch block, whereas baseline pre-excitation may be subtle. The term covers an anatomical and electrophysiological field that must be specified: not every wide-complex tachycardia with this morphology depends on such a pathway, nor do all atypical connections have the same significance.
Junctional tachycardia originates in the atrioventricular junction and must be distinguished from AV nodal re-entry. Atrial activity may follow the ventricle, precede it with variable relationships, or dissociate. Accelerated junctional rhythm is a different phenomenon from rapid sustained junctional tachycardia, although they share the general site of the generator. Interpretation requires an age-adjusted rate, temporal behavior and clinical context, without assigning the same meaning to every apparent absence of a P wave.
Junctional ectopic tachycardia, or JET, is particularly important in congenital forms and in the period after pediatric cardiac surgery. Loss of atrioventricular synchrony can contribute to hemodynamic compromise. Because the generator is often automatic, interventions capable of interrupting a nodal re-entry circuit may not permanently eliminate this arrhythmia. Management considers temperature, catecholamines, metabolic balance, cardiac function and the possibility of restoring a favorable atrioventricular sequence.
Focal and macroreentrant atrial tachycardias complete the anatomical supraventricular spectrum, but the atrioventricular node usually serves as the connection to the ventricles. A focal atrial tachycardia may continue during atrioventricular block; in atrial flutter, 2:1 conduction may conceal part of the atrial activity and mimic a regular paroxysmal tachycardia. Recognizing these possibilities preserves a coherent classification even when the initial ECG does not display all elements of the mechanism.
Supraventricular tachycardia does not necessarily imply a structural lesion detectable by echocardiography. Dual AV nodal physiology or a subtle accessory connection can sustain clinically important arrhythmias in a heart with normal chambers, valves and systolic function. The term “healthy heart” should be interpreted as the absence of documented structural heart disease, not the absence of an electrical substrate. A reassuring echocardiogram therefore does not replace rhythm documentation.
Accessory pathways are congenital connections crossing the fibrous insulation that separates atria and ventricles. Their clinical expression depends on location, direction of conduction, refractoriness and competition with the atrioventricular node. A pathway may become evident only under certain conditions of rate or autonomic tone; in other cases it remains concealed because it does not conduct anterogradely. Occasional disappearance of pre-excitation alone does not justify concluding that risk is zero, because observed behavior may also depend on fusion and the conditions at that moment.
Some congenital heart diseases alter the likelihood and complexity of accessory pathways. Ebstein anomaly is a relevant association, including because of multiple connections and altered tricuspid annular anatomy. In adults with repaired congenital heart disease, scar-related atrial re-entry circuits may coexist with AV nodal or accessory mechanisms. Assessment therefore includes reconstruction of the native and surgical anatomy required to interpret the ECG and plan safe access.
An isolated family history of palpitations is poorly specific. Genetic assessment becomes more relevant when pre-excitation, hypertrophy, conduction disease, muscle disease or sudden deaths cluster in the same patient or family. Phenotypes associated with storage diseases or inherited syndromes should not be reduced to a diagnosis of isolated WPW. In common sporadic AVNRT, by contrast, indiscriminate genetic panel testing is not a routine part of assessment and may produce findings of uncertain significance without changing management.
Acquired conditions can increase triggers or worsen tolerance of a pre-existing circuit. Fever, dehydration, anemia, hyperthyroidism, pain and sympathomimetics increase adrenergic load; electrolyte abnormalities and drug toxicity can promote ectopy and electrical instability. The causal relationship must be demonstrated in context: finding a precipitating condition does not remove the need to define the rhythm, and correcting it does not guarantee permanent disappearance of a re-entry pathway.
Pregnancy changes circulating volume, heart rate, autonomic tone and sensitivity to arrhythmic stimuli. A previously known tachycardia may become more frequent or present for the first time. Assessment must separate physiological sinus acceleration from a paroxysmal arrhythmia and consider maternal well-being, perfusion and treatment safety. In recurrent forms recognized before conception, preventive discussion of definitive options can reduce the need for therapy during pregnancy.
Age modifies presentation. In infants, sustained tachycardia may present with feeding difficulty, pallor, irritability or heart failure without a description of palpitations. In older patients, a rate that is not exceptionally high may cause hypotension because of reduced diastolic reserve, valvular stenosis or coronary disease. The subjective intensity of palpitations therefore does not measure risk, and the same ventricular rate may have profoundly different consequences among individuals.
In athletes, assessment includes the relationship with exertion, any syncope and pre-excitation, in addition to the desired performance level and sport. In occupations where sudden loss of control could endanger other people, tolerability of episodes in daily life may not be sufficient to define an acceptable risk. These contexts may justify more detailed stratification without turning every benign tachycardia into an indiscriminate contraindication to physical activity.
Psychological factors influence perception, quality of life and behavior during episodes but do not replace electrocardiographic diagnosis. Anxiety may precede an episode, follow it or be independent of the rhythm. Prematurely attributing sudden palpitations to an emotional disorder may delay documentation of a treatable tachycardia. Recording a tachycardia on one occasion does not, however, demonstrate that every subsequent symptom has the same mechanism.
The diagnostic pathway begins with a precise temporal description. Sudden onset, the sensation of a very regular rapid heartbeat and equally abrupt termination favor a re-entry tachycardia; a gradual increase parallel to fever, exertion or hypovolemia suggests sinus acceleration more strongly. None of these features is absolute. The patient may notice the onset late, a focal tachycardia may occur in bursts, and a recording started after the episode is already underway may conceal the decisive dynamics.
The history should reconstruct duration, frequency of episodes, circumstances of onset, medications taken and mode of termination. Syncope, persistent chest pain, marked dyspnea and impaired perfusion change the priority of assessment. It is useful to retrieve previous tracings and documentation of effective treatments, distinguishing the label reported by the patient from the diagnosis actually recorded. The generic term “tachycardia” on a discharge summary does not identify the circuit, whereas a brief preserved ECG may provide durable information.
Physical examination first assesses hemodynamic stability, level of consciousness, blood pressure and signs of congestion. Heart rate and pulse regularity are initial elements, not a sufficient classification. Prominent neck pulsations may reflect atrial contraction against closed atrioventricular valves and support suspicion of AVNRT, but they are not pathognomonic. Murmurs, signs of congenital heart disease, thyroid abnormalities or congestion guide evaluation of the context in which the arrhythmia develops.
The twelve-lead ECG during the episode is the most useful document for initial orientation. Interpretation considers regularity, QRS duration and morphology, atrial activity, the atrioventricular relationship and RP and PR intervals. Atrial waves that are difficult to recognize in one lead may be evident in another. Comparing the ECG during tachycardia with the sinus ECG helps distinguish a small retrograde atrial deflection from a ventricular component already present at baseline.
A short- or long-RP relationship narrows the field but is not itself a diagnosis. A retrograde P wave very close to the QRS is common in typical AVNRT; a later, more separated P wave may accompany orthodromic AVRT. Long-RP tachycardias include atrial tachycardia, atypical AVNRT and PJRT. P-wave morphology and the effect of changes in conduction complete the interpretation. Timing thresholds used in algorithms are operational tools and should be applied to a sufficiently readable tracing.
A wide QRS requires an independent line of reasoning. Ventricular tachycardia remains a priority possibility, especially in the presence of structural heart disease; preserved blood pressure and young age are insufficient to exclude it. Supraventricular alternatives include pre-existing bundle branch block, rate-dependent aberrancy and pre-excitation. Diagnostic uncertainty should be reflected in therapeutic choice: a drug appropriate for a narrow-complex nodal tachycardia cannot automatically be transferred to every rapid wide-complex rhythm.
The baseline ECG is assessed for pre-excitation, conduction disturbances, signs of hypertrophy and abnormalities suggesting heart disease. An isolated short PR interval does not demonstrate an accessory pathway; assessment of pre-excitation integrates QRS onset, delta wave and distribution of changes. The absence of these findings does not exclude a concealed pathway. When pre-excitation is intermittent, comparison among tracings and specialist assessment are more informative than a single apparently normal recording.
Ambulatory monitoring is chosen according to the probability of capturing an episode. A short Holter may be appropriate for daily symptoms but yield little for monthly episodes. Extended or patient-activated recorders increase the observation window; implantable devices have a role in selected circumstances, particularly when infrequent but important symptoms remain unexplained. The report should be based on the tracing and temporal correlation, not merely on the number of episodes recognized by an algorithm.
Wearable devices can document a rhythm during symptoms, but photoplethysmography measures pulsatile changes and does not replace electrical activity. Even a single-lead ECG may be insufficient to separate circuits with an identical ventricular appearance. The recording retains clinical value when preserved in its original form, with adequate duration and quality, and interpreted together with other data. An automated label of regular or irregular rhythm does not exhaust the diagnostic problem.
Echocardiography defines ventricular function, valves and chamber dimensions; blood tests address specific hypotheses such as anemia, electrolyte imbalance or thyroid dysfunction. Not every patient needs ischemia testing or magnetic resonance imaging. Unexpected ventricular dysfunction, congenital heart disease or suspicion of infiltrative disease may instead justify further investigation. Tests should be selected to clarify uncertainty that affects prognosis or treatment, avoiding replacement of clinical reasoning with a standard checklist.
The electrophysiological study records intracardiac activity and uses programmed stimulation, activation sequences and responses to controlled perturbations to define the mechanism. An induced tachycardia is compared with the clinical form, because the presence of an inducible circuit does not automatically demonstrate that it explains all symptoms. When the indication is agreed, diagnosis and ablation can occur during the same procedure. In non-inducible cases, the decision depends on available documentation and the strength of indirect evidence, not on an automatic rule.
Therapy pursues different goals: terminating an episode, reducing recurrences, eliminating the substrate, preventing complications and restoring quality of life. An intervention effective for the first goal may not affect the others. Conversion with an AV nodal drug, for example, does not eliminate an accessory pathway; the absence of palpitations after treatment does not necessarily demonstrate that a previously incessant arrhythmia has disappeared. The strategy should therefore be explicitly linked to the problem it is intended to solve.
When instability is attributable to tachycardia, rapid restoration of an effective rhythm takes priority over complete circuit definition. Synchronized cardioversion is the reference treatment for many tachyarrhythmias with a pulse and hemodynamic compromise. In stable patients, vagal maneuvers and adenosine may terminate tachycardias dependent on the atrioventricular node, but require correct identification of the presentation and assessment of contraindications. The response should be recorded because it may provide useful information even when conversion does not occur.
AV nodal treatment is less directly curative when the generator is atrial or junctional and automatic. Slowing conduction may improve the ventricular response in atrial tachycardia, whereas it may be insufficient in JET with atrioventricular dissociation. Automatic forms may recur immediately after cardioversion if the generator remains active. In such cases, correction of the physiological context, selection of appropriate drugs and, when indicated, targeted treatment of the focus become central.
Pre-excited atrial fibrillation illustrates why the mechanism must precede drug selection. The atrioventricular node is not the only route to the ventricles; selectively reducing its conduction may facilitate a very rapid response through the accessory pathway. Management therefore follows a specific pathway, with cardioversion when necessary and drugs that do not rely solely on AV nodal blockade in selected situations. The general label of supraventricular tachycardia does not make AV nodal therapy safe in this context.
For rare, brief and well-tolerated episodes, observation may be reasonable after risk assessment and discussion of preferences. It does not mean absence of a plan: methods of documentation, instructions for recurrences and criteria for reconsidering the decision are needed. Increased duration, onset of syncope or new heart disease may alter the balance. In patients with pre-excitation, the decision must include pathway properties and not be based only on symptom intensity.
Pharmacological prevention uses AV nodal or antiarrhythmic drugs selected according to the circuit, ventricular function and comorbidities. Bradycardia, hypotension, bronchospasm, conduction disorders and interactions limit some treatments. Class Ic drugs require particular attention to structural or ischemic heart disease and proarrhythmic risk. Amiodarone is not a routine solution for common paroxysmal tachycardia that can be treated with more targeted options, given cumulative toxicity and the availability of ablation.
Catheter ablation aims to interrupt an indispensable pathway or eliminate the focus. In AVNRT, the usual target is the slow pathway, preserving physiological atrioventricular conduction. In AVRT, the accessory connection is treated; in focal tachycardias, the site of origin is identified. In atrial macroreentry, the target may be a critical isthmus between anatomical or scar barriers. Target location explains why efficacy and risks are not uniform across all supraventricular tachycardias.
Proximity to the atrioventricular node, coronary arteries or other structures modifies the procedural strategy. Radiofrequency and cryoenergy have different properties and may be selected according to anatomy, age and center experience. Three-dimensional mapping and low-radiation techniques assist navigation but do not eliminate the need for correct electrophysiological diagnosis. Safety also depends on vascular access, management of procedural anticoagulation when required and the ability to recognize a complication promptly.
Elimination of an accessory pathway is not equivalent to ablation of the atrioventricular node. The latter deliberately interrupts conduction to the ventricles and requires a permanent pacing strategy; it is not the usual treatment for AVNRT or AVRT. An accurate explanation to the patient should make clear the difference between the target responsible for the arrhythmia and the normal conduction system intended to be preserved. The risk of iatrogenic block should be discussed in relation to the specific site and procedure.
Thromboembolic prevention is not applied indiscriminately to all rapid arrhythmias. Isolated AVNRT and AVRT do not automatically create an indication for chronic anticoagulation. Concomitant atrial fibrillation or flutter, a prosthetic valve or other conditions may require independent treatment. Antithrombotic therapy around an ablation also depends on the type of procedure and chambers involved. Keeping these issues separate avoids both unwarranted prescriptions and interruption of necessary therapy for a different problem.
Many paroxysmal reentrant tachycardias have a favorable prognosis in the absence of heart disease, especially when the mechanism is defined and treatable. This does not make repeated episodes, emergency visits, interruption of work and fear of recurrence irrelevant. Quality of life is an independent clinical outcome and may justify definitive treatment even when the risk of sudden death is low. The decision should therefore integrate safety, episode frequency and personal impact.
Hemodynamic tolerance depends on duration, rate and atrioventricular synchrony, but also on diastolic function, coronary reserve and valvular disease. Tachycardia can reduce filling, increase oxygen demand and cause hypotension; atrial contraction at an unfavorable phase can amplify the disturbance. The occurrence of syncope requires assessment of the circumstances, because it may result from tachycardia, a pause after conversion, a reflex mechanism or a different arrhythmia.
Tachycardia-induced cardiomyopathy is particularly important in incessant forms or those with a high burden. A moderately elevated rate sustained for a long time may impair ventricular function even without dramatic episodes. Altered metabolism, intracellular calcium handling, neurohormonal activation and remodeling contribute to deterioration. PJRT and persistent focal tachycardias deserve attention precisely because the patient may adapt to the rhythm and report few symptoms while function worsens.
Improvement after arrhythmia control supports a reversible component but does not exclude pre-existing heart disease. Recovery should be documented by clinical and instrumental reassessment and may take time. In patients with prior dysfunction, a recurrence may have more rapid consequences than those observed during the first episode. Follow-up should therefore verify both the absence of clinically significant tachycardia and the evolution of ventricular function, maintaining heart-failure therapies according to the overall picture.
Pre-excitation introduces a risk distinct from simple recurrence of re-entry. A pathway capable of transmitting closely spaced impulses may expose the patient to dangerous ventricular rates during atrial fibrillation. Electrophysiological properties, multiple pathways, inducible arrhythmias and clinical context contribute to risk stratification. Intermittent or exercise-related loss of pre-excitation may provide information, but it must be interpreted correctly and is not equivalent to a universal guarantee of safety.
After ablation, occasional palpitations do not necessarily demonstrate return of the circuit. Premature beats and sinus accelerations may persist, and increased attention to the heartbeat may make them more noticeable. Recurrence of prolonged episodes with features similar to the prior arrhythmia instead requires documentation. This distinction prevents both calling a procedure unsuccessful on the basis of symptoms alone and, conversely, automatically attributing every recurrence to an innocent phenomenon.
Treatment complications include drug effects, proarrhythmia and procedural risks. Hypotension and bradycardia may make prophylaxis less tolerable than the episodes; drug accumulation and interactions may emerge when renal function changes or new therapies are introduced. Ablation carries vascular risks and, depending on the site, pericardial, thromboembolic or conduction injury. Consent should compare these risks with those of untreated arrhythmia in the individual patient.
An effective care pathway preserves the diagnosis, a representative ECG and procedural results in accessible documentation. The clinical letter should indicate which rhythm was observed, whether pre-excitation is present and which treatments worked or caused problems. This information reduces the likelihood that a subsequent episode will be managed as entirely new. It is especially important for people who travel, pediatric patients transitioning to adult services and those with complex congenital heart disease.
Education includes recognition of usual symptoms, agreed methods of recording and warning signs that require urgent care. The ability to perform a learned vagal maneuver should not delay assessment of syncope, persistent chest pain or significant dyspnea. An individualized plan helps avoid both disproportionate alarm over isolated sensations and prolonged attempts at self-management during a poorly tolerated episode. Periodic reassessment keeps treatment aligned with clinical evolution and the person’s preferences.
Nota informativa: le informazioni contenute in questa pagina hanno esclusivamente finalità informative e divulgative e non sostituiscono il parere, la diagnosi o il trattamento di un medico. In caso di necessità, rivolgersi sempre a un professionista sanitario qualificato.
Trasparenza sull'intelligenza artificiale: questa pagina è stata realizzata con il supporto di strumenti di intelligenza artificiale, utilizzati come ausilio nella produzione e nell'elaborazione dei contenuti.